Revelation Pharma Achieves Full Accreditation for PGY1 Residency Program
This exciting news marks a significant milestone for the only pharmacy residency program in the U.S. focused on compounding, which has received the maximum accreditation duration of eight years.
Commitment to Exceptional Pharmacy Training
Revelation Pharma, a prominent name in the national network of compounding pharmacies, recently announced its PGY1 Community-Based Pharmacy Residency Program has secured full accreditation for the maximum duration of eight years. This honor comes from the American Society of Health-System Pharmacists (ASHP) in partnership with the Accreditation Council for Pharmacy Education (ACPE).
This achievement highlights Revelation Pharma's unwavering commitment to excellence in education and advancing pharmaceutical compounding practices. As the landscape of healthcare evolves, so does the need for specialized training in compounding pharmacy.
Innovative Residency Structure
CEO Shawn Hodges expressed pride in the residency program, noting that it bridges clinical pharmacy and advanced compounding. This collaboration provides residents with an unmatched educational experience across diverse areas of pharmacy practice, improving their readiness for future roles in healthcare.
The PGY1 program offers a comprehensive approach, allowing residents to gain practical experience in both sterile and non-sterile compounding, regulatory compliance, quality assurance, and clinical management. Additionally, they engage with a wide array of therapeutic areas through Revelation Pharma's extensive network of pharmacies.
Recognizing the Efforts of Staff and Residents
Brandon Sucher, National Director of Clinical Outcomes, emphasized that achieving this eight-year accreditation reflects the dedication shown by preceptors, leaders, and residents alike, all working tirelessly to maintain the highest standards within the industry. Such recognition not only validates the program's strength but also ensures its sustainability in the ever-changing healthcare environment.
Revelation Pharma is committed to excellence in compounding, with a focus on innovation, collaboration, and education—all crucial components that contribute positively to patient outcomes nationally. Their approach redefines standards for pharmacy education and practice.
Continuing to Lead in Compounding Pharmacy
Through this accreditation, Revelation Pharma continues to set benchmarks in the pharmaceutical industry, encouraging continual growth and improvement in compounding practices. Their focus on personalized medicine emphasizes quality and innovative care.
About Revelation Pharma
Revelation Pharma is distinguished within the national network of 503A and 503B compounding pharmacies. It serves patients across the United States, enhancing healthcare through tailored therapies in various fields such as women's and men's health, dermatology, and more. The dedication to patient-centered approaches is at the heart of Revelation Pharma's mission and values.
For more information on Revolution Pharma's PGY1 Residency Program, visit their official website.
Frequently Asked Questions
What is the duration of the accreditation received by Revelation Pharma's residency program?
The program has been accredited for the maximum duration of eight years.
What does the residency program at Revelation Pharma offer?
The program provides hands-on training in sterile and non-sterile compounding, quality assurance, and regulatory compliance.
Who oversees the PGY1 residency program?
The program is overseen by experienced preceptors and healthcare professionals committed to maintaining high standards of pharmacy education.
How does Revelation Pharma ensure the quality of its residency program?
Quality is ensured through rigorous training, evaluation, and ongoing support from the leadership and clinical outcomes team.
What areas of pharmacy does Revelation Pharma focus on?
The company specializes in numerous therapeutic areas, including women's health, pain management, and personalized medicine.
